SG11201908128YA - Subcutaneous administration of a p2y12 receptor antagonist - Google Patents
Subcutaneous administration of a p2y12 receptor antagonistInfo
- Publication number
- SG11201908128YA SG11201908128YA SG11201908128YA SG11201908128YA SG 11201908128Y A SG11201908128Y A SG 11201908128YA SG 11201908128Y A SG11201908128Y A SG 11201908128YA SG 11201908128Y A SG11201908128Y A SG 11201908128YA
- Authority
- SG
- Singapore
- Prior art keywords
- idorsia
- allschwil
- hegenheimermattweg
- international
- pharmaceuticals
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 238000007920 subcutaneous administration Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 8
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000594009 Phoxinus phoxinus Species 0.000 abstract 1
- MVHTVXFDPMHZNE-UHFFFAOYSA-N cyclopentane-1,2,3-triol Chemical compound OC1CCC(O)C1O MVHTVXFDPMHZNE-UHFFFAOYSA-N 0.000 abstract 1
- VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 abstract 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908128YA true SG11201908128YA (en) | 2019-10-30 |
Family
ID=61899166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908128Y SG11201908128YA (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11179390B2 (uk) |
| EP (1) | EP3595666A1 (uk) |
| JP (2) | JP2020510043A (uk) |
| KR (1) | KR102510832B1 (uk) |
| CN (1) | CN110381947A (uk) |
| AU (1) | AU2018234056B2 (uk) |
| BR (1) | BR112019014567A2 (uk) |
| CA (1) | CA3050831A1 (uk) |
| CL (1) | CL2019002318A1 (uk) |
| EA (1) | EA201992123A1 (uk) |
| IL (1) | IL269286B2 (uk) |
| MA (1) | MA49887A (uk) |
| MX (1) | MX2019009559A (uk) |
| PH (1) | PH12019502111A1 (uk) |
| SG (1) | SG11201908128YA (uk) |
| TW (1) | TWI765002B (uk) |
| UA (1) | UA125531C2 (uk) |
| WO (1) | WO2018167139A1 (uk) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62946B1 (sr) | 2016-09-22 | 2022-03-31 | Idorsia Pharmaceuticals Ltd | Kristalni oblici |
| KR20230041732A (ko) | 2020-07-15 | 2023-03-24 | 이도르시아 파마슈티컬스 리미티드 | P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물 |
| KR20240033005A (ko) | 2021-07-13 | 2024-03-12 | 이도르시아 파마슈티컬스 리미티드 | 4-((r)-2-｛[6-((s)-3-메톡시-피롤리딘-1-일)-2-페닐-피리미딘-4-카르보닐]-아미노｝-3-포스포노-프로피오닐)-피페라진-1-카르복실산부틸 에스테르의 합성 방법 |
| WO2023174810A1 (en) | 2022-03-14 | 2023-09-21 | Idorsia Pharmaceuticals Ltd | A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870035A (en) | 1970-07-17 | 1975-03-11 | Survival Technology | Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US5078680A (en) | 1984-08-08 | 1992-01-07 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| GR861289B (en) | 1985-05-20 | 1986-09-16 | Survival Technology | Injection method and apparatus with electrical blood absorbing stimulation |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| DE60333866D1 (de) | 2002-12-11 | 2010-09-30 | Bayer Schering Pharma Ag | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten |
| CA2521313A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| WO2005002574A1 (en) * | 2003-06-24 | 2005-01-13 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| NZ568335A (en) | 2005-10-21 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| EP2148871A1 (en) | 2007-04-23 | 2010-02-03 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| KR20100029746A (ko) | 2007-05-02 | 2010-03-17 | 포톨라 파마슈티컬스, 인코포레이티드 | 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여 |
| BRPI0819696B1 (pt) | 2007-11-29 | 2018-10-23 | Actelion Pharmaceuticals Ltd | compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| MA33260B1 (fr) | 2009-04-08 | 2012-05-02 | Actelion Pharmaceuticals Ltd | 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines |
| KR101728180B1 (ko) | 2009-04-22 | 2017-04-18 | 액테리온 파마슈티칼 리미티드 | 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도 |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2011160768A1 (en) | 2010-06-23 | 2011-12-29 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
| RS62946B1 (sr) | 2016-09-22 | 2022-03-31 | Idorsia Pharmaceuticals Ltd | Kristalni oblici |
-
2018
- 2018-03-14 AU AU2018234056A patent/AU2018234056B2/en active Active
- 2018-03-14 WO PCT/EP2018/056372 patent/WO2018167139A1/en unknown
- 2018-03-14 BR BR112019014567-2A patent/BR112019014567A2/pt unknown
- 2018-03-14 TW TW107108546A patent/TWI765002B/zh active
- 2018-03-14 CN CN201880017104.XA patent/CN110381947A/zh active Pending
- 2018-03-14 EP EP18715499.2A patent/EP3595666A1/en active Pending
- 2018-03-14 CA CA3050831A patent/CA3050831A1/en active Pending
- 2018-03-14 UA UAA201910293A patent/UA125531C2/uk unknown
- 2018-03-14 MA MA049887A patent/MA49887A/fr unknown
- 2018-03-14 SG SG11201908128Y patent/SG11201908128YA/en unknown
- 2018-03-14 JP JP2019549420A patent/JP2020510043A/ja active Pending
- 2018-03-14 EA EA201992123A patent/EA201992123A1/ru unknown
- 2018-03-14 MX MX2019009559A patent/MX2019009559A/es unknown
- 2018-03-14 KR KR1020197029753A patent/KR102510832B1/ko active IP Right Grant
- 2018-03-14 US US16/494,254 patent/US11179390B2/en active Active
-
2019
- 2019-08-16 CL CL2019002318A patent/CL2019002318A1/es unknown
- 2019-09-11 IL IL269286A patent/IL269286B2/en unknown
- 2019-09-13 PH PH12019502111A patent/PH12019502111A1/en unknown
-
2023
- 2023-01-23 JP JP2023008155A patent/JP2023052576A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018167139A1 (en) | 2018-09-20 |
| EA201992123A1 (ru) | 2020-02-25 |
| KR20190124297A (ko) | 2019-11-04 |
| TWI765002B (zh) | 2022-05-21 |
| JP2023052576A (ja) | 2023-04-11 |
| US20200129510A1 (en) | 2020-04-30 |
| MX2019009559A (es) | 2019-10-15 |
| IL269286B2 (en) | 2023-08-01 |
| IL269286A (en) | 2019-11-28 |
| AU2018234056A1 (en) | 2019-10-31 |
| EP3595666A1 (en) | 2020-01-22 |
| TW201840323A (zh) | 2018-11-16 |
| AU2018234056B2 (en) | 2023-05-25 |
| KR102510832B1 (ko) | 2023-03-15 |
| CA3050831A1 (en) | 2018-09-20 |
| CN110381947A (zh) | 2019-10-25 |
| IL269286B1 (en) | 2023-04-01 |
| MA49887A (fr) | 2020-06-24 |
| BR112019014567A2 (pt) | 2020-02-18 |
| UA125531C2 (uk) | 2022-04-13 |
| PH12019502111A1 (en) | 2020-03-16 |
| US11179390B2 (en) | 2021-11-23 |
| JP2020510043A (ja) | 2020-04-02 |
| CL2019002318A1 (es) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908128YA (en) | Subcutaneous administration of a p2y12 receptor antagonist | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808214TA (en) | Pyrazolopyrimidine derivatives | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers |